Direct in utero engineering of mouse models
The LIMITLESS project aims to develop a whole-embryo gene editing technology for in utero manipulation, enhancing life sciences research while reducing ethical and financial burdens of mouse models.
Projectdetails
Introduction
Mouse models are a gold standard for life sciences research, spanning developmental biology, cancer studies, and pre-clinical testing, but they also have important limitations. Mouse colony maintenance is expensive, and the large colonies needed are ethically problematic.
Limitations of Mouse Models
Approaches aiming for cell-type specific manipulations can be confounded by:
- Leaky promoters
- Off-target/unknown promoter expression
- Endogenous Cre sites
- Cre toxicity
Finally, mouse strains generated in different inbred genetic backgrounds yield confounding results when interbred, or necessitate extensive back-crossing, which again leads to large usage of mice. An alternative strategy to generate mouse models, circumventing these issues, is direly needed.
NEPTUNE Technology
To solve this problem for the mouse nervous system, we previously developed neural plate targeting with in utero nano-injection (NEPTUNE). NEPTUNE targets 95% of cells in the brain, can recapitulate established mouse models, and can be used flexibly for cell-type specific manipulations.
LIMITLESS Project
In LIMITLESS, my lab will leverage our expertise in ultra-high titer viral production, developmental biology, and technology development to go beyond the state of the art and develop a technology for whole-embryo editing in utero. We will combine this technology with next generation single cell lineage tracing to resolve the “family tree” of all cell types in developing embryos, providing both fundamental new knowledge and information that is leverageable for further development of the technique.
Conclusion
In sum, my lab will develop a much-needed technology for whole embryo genetic manipulation, opening the door to limitless new types of experiments. Direct in utero whole-embryo gene editing would accelerate life sciences research, reduce the financial and ethical costs of animal work, and enable experiments currently beyond reach with existing technology.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.265.000 |
Totale projectbegroting | € 2.265.000 |
Tijdlijn
Startdatum | 1-5-2025 |
Einddatum | 30-4-2030 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- KAROLINSKA INSTITUTETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Towards Artificial Human Embryoid Models: Engineered and Synthetic Platforms for Ex Utero Mammalian EmbryogenesisDevelop biotechnological platforms to culture mammalian embryos ex utero and create synthetic embryoids for advancing stem cell research and disease modeling. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Uncovering the role and regulation of 3D DNA-RNA nuclear dynamics in controlling cell fate decisionsThis project aims to elucidate the interplay between 3D genome organization and transcriptome dynamics in early mouse embryos to identify factors influencing cell fate decisions. | ERC Starting... | € 1.500.000 | 2023 | Details |
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain DiseasesThis project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively. | ERC Consolid... | € 2.249.895 | 2022 | Details |
A sonogenetic brain-machine interface for neurosciences and visual restorationDeveloping a novel sonogenetic brain-machine interface for remote, precise control of neuronal networks in large primate brains to advance treatments for neurological disorders. | ERC Synergy ... | € 7.817.939 | 2024 | Details |
Prime editing to Repair Inherited Metabolic Errors: in vivo gene correction for human genetic diseaseDevelop an in vivo prime editing therapy for methylmalonic acidemia to correct genetic mutations in the liver, aiming for safe, efficient, and personalized treatments before irreversible damage occurs. | ERC Starting... | € 1.499.968 | 2022 | Details |
Towards Artificial Human Embryoid Models: Engineered and Synthetic Platforms for Ex Utero Mammalian Embryogenesis
Develop biotechnological platforms to culture mammalian embryos ex utero and create synthetic embryoids for advancing stem cell research and disease modeling.
Uncovering the role and regulation of 3D DNA-RNA nuclear dynamics in controlling cell fate decisions
This project aims to elucidate the interplay between 3D genome organization and transcriptome dynamics in early mouse embryos to identify factors influencing cell fate decisions.
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases
This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.
A sonogenetic brain-machine interface for neurosciences and visual restoration
Developing a novel sonogenetic brain-machine interface for remote, precise control of neuronal networks in large primate brains to advance treatments for neurological disorders.
Prime editing to Repair Inherited Metabolic Errors: in vivo gene correction for human genetic disease
Develop an in vivo prime editing therapy for methylmalonic acidemia to correct genetic mutations in the liver, aiming for safe, efficient, and personalized treatments before irreversible damage occurs.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing systemThe NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases. | EIC Pathfinder | € 2.988.377 | 2023 | Details |
New Prime Editing and non-viral delivery strategies for Gene TherapyThis project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders. | EIC Pathfinder | € 4.406.097 | 2022 | Details |
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATIONREGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration. | EIC Pathfinder | € 2.943.233 | 2024 | Details |
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system
The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.
New Prime Editing and non-viral delivery strategies for Gene Therapy
This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION
REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.